30 September 2022 (Friday) -Transfusion News Update

The nice people at “Transfusion News” sent their update today. As always, all good stuff…

Iron Repletion Does Not Effect Donor Well-Being or Red Cell Quality

Transfusion News Image 1
September 28, 2022
Iron deficiency develops in over one third of regular, repeat blood donors. In order to exam the physiological consequences of iron deficiency in blood donors, a randomized, double-blind, placebo-controlled trial (Donor Iron Deficiency Study [DIDS]) screened 2,011 adult blood donors. [Read More]
Join us to hear about sickle cell disease and the risk of hemolytic transfusion reactions
Transfusion News Image 1
In this new Transfusion Science Webinar, Karina Yazdanbakhsh, PhD, will discuss our current understanding of hemolytic transfusion reactions (HTR) in patients with sickle cell disease, with a focus on potential pathophysiologic mechanisms, recommended approaches to managing HTR, and strategies to prevent the development of HTR. [Register Now]

Sickle Cell Disease Advocacy- Live Twitter Space Event Today
Transfusion News Image 1
Join Transfusion News Associate Editors Daniela Hermelin and Monica Pagano on Twitter Space this Friday September 30 at 11:00 AM ET for a #Blooducation Baristas live event. Dr. Hermelin and Dr. Pagano will be joined by Richard Godby, Tiffani Skinner-Jackson and Patrick McGann to discuss Sickle Cell Disease Advocacy. [Set a reminder to join us]
Prophylactic Tranexamic Acid Does Not Decrease Bleeding or Transfusions in Patients with Hematologic Malignancies
Transfusion News Image 1
September 21, 2022
Patients with hematologic malignancies account for 43% of the 2 million platelet doses transfused in the U.S. each year. Despite prophylactic platelet transfusions, 43% of patients with hematologic malignancies still experience WHO grade 2 bleeding or higher. Tranexamic acid (TXA) is commonly used to prevent bleeding and mortality in a many patients including orthopedic, cardiothoracic, organ transplant, trauma, and obstetrical. [Read More]


No comments:

Post a Comment